Challenges and Opportunities for Pancreatic Cancer Immunotherapy.
Pancreatic ductal adenocarcinoma (PDA) is among the most immune-resistant tumor types. Its unique genomic landscape shaped by oncogenic drivers promotes immune suppression from the earliest stages of tumor inception to subvert adaptive T cell immunity. Single-agent immune modulators have thus far proven clinically ineffective, and multi-modal therapies targeting mechanisms of immunotherapy resistance are likely needed. Here, we review novel immunotherapy strategies currently under investigation to (1) confer antigen specificity, (2) enhance T cell effector function, and (3) neutralize immunosuppressive elements within the tumor microenvironment that may be rationally combined to untangle the web of immune resistance in PDA and other tumors.
['Bear|Adham S|AS|', 'Vonderheide|Robert H|RH|', "O'Hara|Mark H|MH|"]
D000818:Animals D021441:Carcinoma, Pancreatic Ductal D002986:Clinical Trials as Topic D019008:Drug Resistance, Neoplasm D006801:Humans D007167:Immunotherapy D010190:Pancreatic Neoplasms D019139:Tumor Escape D059016:Tumor Microenvironment
pancreatic cancer immunotherapy